CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
Follow CRSP
CRISPR Therapeutics AG (CRSP) EV/Sales
As of 16 October 2026, CRISPR Therapeutics AG (CRSP) trades at a EV/Sales of 223×. Over the past ten years it has ranged from −26.0× (February 2017) to 16,984× (January 2021); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 845× | 1,819.01% |
| FY2024 | 44.0× | 334.09% |
| FY2023 | 10.1× | (99.24%) |
| FY2022 | 1,336× | 33,951.78% |
| FY2021 | 3.9× | (99.97%) |
| FY2020 | 11,763× | 141,051.13% |
| FY2019 | 8.3× | (97.15%) |
| FY2018 | 292× | 1,460.29% |
| FY2017 | 18.7× | — |
| FY2016 | −7.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 260× | (60.63%) |
| Mar 2026 | 661× | (21.78%) |
| Dec 2025 | 845× | 666.28% |
| Sep 2025 | 110× | 53.13% |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| TVTX Travere Therapeutics, Inc. compare | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| SRRK Scholar Rock Holding Corporation compare | 104× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG | 223× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)